Candriam Luxembourg S.C.A. Cuts Stake in Davita Inc (DVA)
Candriam Luxembourg S.C.A. lessened its position in shares of Davita Inc (NYSE:DVA) by 93.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,945 shares of the company’s stock after selling 53,744 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Davita were worth $214,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the company. Federated Investors Inc. PA grew its position in shares of Davita by 2,796.3% during the 3rd quarter. Federated Investors Inc. PA now owns 107,451 shares of the company’s stock valued at $7,697,000 after purchasing an additional 103,741 shares in the last quarter. State of Alaska Department of Revenue grew its position in shares of Davita by 14.8% during the 4th quarter. State of Alaska Department of Revenue now owns 42,998 shares of the company’s stock valued at $2,212,000 after purchasing an additional 5,545 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Davita during the 4th quarter valued at $262,000. Oakbrook Investments LLC grew its position in shares of Davita by 60.5% during the 4th quarter. Oakbrook Investments LLC now owns 12,950 shares of the company’s stock valued at $666,000 after purchasing an additional 4,880 shares in the last quarter. Finally, Bank of Montreal Can grew its position in shares of Davita by 18.3% during the 4th quarter. Bank of Montreal Can now owns 304,448 shares of the company’s stock valued at $15,666,000 after purchasing an additional 47,013 shares in the last quarter. 90.78% of the stock is owned by institutional investors and hedge funds.
A number of research firms have recently commented on DVA. Zacks Investment Research upgraded shares of Davita from a “sell” rating to a “hold” rating in a research report on Thursday, February 21st. Robert W. Baird reduced their price target on shares of Davita from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Friday, February 15th. They noted that the move was a valuation call. SunTrust Banks restated a “hold” rating on shares of Davita in a research report on Wednesday, February 20th. Finally, Deutsche Bank reduced their price target on shares of Davita from $68.00 to $66.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. One analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $67.78.
Davita (NYSE:DVA) last announced its earnings results on Tuesday, May 7th. The company reported $0.91 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.95 by ($0.04). Davita had a return on equity of 13.96% and a net margin of 1.15%. The company had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.82 billion. During the same quarter last year, the firm posted $1.05 earnings per share. The firm’s revenue was down 3.7% on a year-over-year basis. Sell-side analysts predict that Davita Inc will post 4.26 EPS for the current year.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More: What is an Initial Public Offering (IPO)?
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.